GeneDx Holdings (WGS) Net Income towards Common Stockholders (2020 - 2026)

GeneDx Holdings (WGS) has reported Net Income towards Common Stockholders for 7 consecutive years, with -$17.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 264.12% year-over-year to -$17.7 million in Q2 2026; TTM through Jun 2026 was -$106.4 million, a 7664.72% decrease from a year earlier, with the FY2025 full-year figure at -$21.0 million, up 59.8% from the prior year.
• Net Income towards Common Stockholders was -$17.7 million for Q2 2026 at GeneDx Holdings, up from -$63.3 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at $10.8 million in Q2 2025 and troughed at -$308.7 million in Q4 2022.
• A 5-year average of -$48.8 million and a median of -$27.5 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• Across the five-year window, Net Income towards Common Stockholders surged 137.06% in 2025 and plunged 869.81% in 2026, its largest moves.
• Over 5 years, Net Income towards Common Stockholders stood at -$308.7 million in 2022, then surged by 91.65% to -$25.8 million in 2023, then jumped by 121.1% to $5.4 million in 2024, then slumped by 424.86% to -$17.7 million in 2025, then declined by 0.42% to -$17.7 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$17.7 million (Q2 2026), -$63.3 million (Q1 2026), and -$17.7 million (Q4 2025), per Business Quant data.